In what has been billed as landmark ruling the Intellectual Property Appellate Board upheld the country's first compulsory licence to NATCO Pharma for Bayer's cancer drug Nexavar recently. In layman language NATCO an Indian pharmaceutical company had been the given the right to copy and sell Bayer's cancer drug Nexavar which costs Rs 2.8 lakh per month. NATCO will sell it for Rs 8880 per month (97% price decrease)! Team Zee Research Group (ZRG) took the opportunity to understand the ramifications of the verdict from Natco Pharma director and chief financial officer P Bhaskara Narayana. Welcoming the judgment Narayana is